{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:09:07Z","timestamp":1787612947326,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.leukres.2021.106715","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T02:53:50Z","timestamp":1632711230000},"page":"106715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era"],"prefix":"10.1016","volume":"110","author":[{"given":"Haizhu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.leukres.2021.106715_bib0005","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2021.106715_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2021.106715_bib0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"G. MabThera International Trial, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.leukres.2021.106715_bib0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-hodgkin\u2019s Lymphoma Prognostic Factors Project, a predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.leukres.2021.106715_bib0025","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2021.106715_bib0030","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2021.106715_bib0035","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.leukres.2021.106715_bib0040","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO.20.01501","article-title":"Diffuse large B-Cell lymphoma\u2019s new genomics: the bridge and the chasm","volume":"38","author":"Crombie","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.leukres.2021.106715_bib0045","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"P. Lymphoma\/Leukemia Molecular Profiling, the use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2021.106715_bib0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2021.106715_bib0055","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2021.106715_bib0060","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2021.106715_bib0065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.leukres.2021.106715_bib0070","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"29","author":"Ciavarella","year":"2018","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2021.106715_bib0075","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2021.106715_bib0080","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1080\/10428190802226425","article-title":"Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma","volume":"49","author":"Cox","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.leukres.2021.106715_bib0085","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2011.112","article-title":"The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma","volume":"25","author":"Wilcox","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2021.106715_bib0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3324\/haematol.2013.088161","article-title":"Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era","volume":"99","author":"Tadmor","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2021.106715_bib0095","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ejh.12221","article-title":"Peripheral blood absolute lymphocyte\/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era","volume":"92","author":"Watanabe","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106715_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2021.106715_bib0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of platelets and platelet receptors in cancer metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2021.106715_bib0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"Stone","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2021.106715_bib0115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ygyno.2020.05.040","article-title":"Nomograms based on the novel platelet index score predict postoperative prognosis in endometrial cancer","volume":"158","author":"Chen","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2021.106715_bib0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218169","article-title":"Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature","volume":"21","author":"Hufnagel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.leukres.2021.106715_bib0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-2141.1998.00818.x","article-title":"Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group","volume":"102","author":"Donadieu","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2021.106715_bib0130","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106715_bib0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"G. Splenic Marginal Zone Lymphoma Study, Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalban","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106715_bib0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clml.2011.09.215","article-title":"Prognostic value of platelet count in diffuse large B-cell lymphoma","volume":"12","author":"Chen","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2021.106715_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-016-2819-3","article-title":"Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma","volume":"96","author":"Ochi","year":"2017","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2021.106715_bib0150","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/09537104.2018.1499889","article-title":"Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era","volume":"30","author":"Nakayama","year":"2019","journal-title":"Platelets"},{"issue":"5","key":"10.1016\/j.leukres.2021.106715_bib0155","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2021.106715_bib0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"L. International Harmonization Project on, Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2021.106715_bib0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2307\/2532740","article-title":"M., Maximally Selected Rank Statistics","volume":"48","author":"Lausen","year":"1992","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.leukres.2021.106715_bib0170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13116","article-title":"A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin","volume":"168","author":"Melchardt","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2021.106715_bib0175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ejh.12529","article-title":"The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients","volume":"95","author":"Troppan","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2021.106715_bib0180","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.leukres.2021.106715_bib0185","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bjh.14237","article-title":"Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum beta2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model","volume":"175","author":"Chen","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2021.106715_bib0190","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3109\/10428194.2014.982642","article-title":"Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"56","author":"Keam","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2021.106715_bib0195","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/annonc\/mdp531","article-title":"M.A. Aloe Spiriti, M.C. Cox, Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story","volume":"21","author":"Bari","year":"2010","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2021.106715_bib0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hon.2757","article-title":"Improving the international prognostic index score using peripheral blood counts: results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma","volume":"38","author":"Marcheselli","year":"2020","journal-title":"Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2021.106715_bib0205","first-page":"1501","article-title":"Independent prognostic value of serum markers in diffuse large B-Cell lymphoma in the era of the NCCN-IPI","volume":"13","author":"Melchardt","year":"2015","journal-title":"J. Compr. Canc. Netw."},{"key":"10.1016\/j.leukres.2021.106715_bib0210","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9651254","article-title":"Prognostic significance of pretreatment Neutrophil\/Lymphocyte ratio and Platelet\/Lymphocyte ratio in patients with diffuse large B-Cell lymphoma","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res. Int."},{"issue":"2","key":"10.1016\/j.leukres.2021.106715_bib0215","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2010.04131.x","article-title":"The platelet contribution to cancer progression","volume":"9","author":"Bambace","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2021.106715_bib0220","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pharmthera.2015.11.005","article-title":"Involvement of platelets in tumor cell metastasis","volume":"157","author":"Tesfamariam","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.leukres.2021.106715_bib0225","first-page":"1","article-title":"Prognostic significance of thrombocytosis in lung cancer: a systematic review and meta-analysis","author":"Ma","year":"2020","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.leukres.2021.106715_bib0230","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1245\/s10434-014-3988-8","article-title":"Clinical significance of thrombocytosis before preoperative chemoradiotherapy in rectal cancer: predicting pathologic tumor response and oncologic outcome","volume":"22","author":"Kim","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2021.106715_bib0235","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10549-017-4463-6","article-title":"Thrombocytosis as a prognostic factor in inflammatory breast cancer","volume":"166","author":"Harano","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.leukres.2021.106715_bib0240","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000495337","article-title":"Prognostic value of platelet count in patients with peripheral t cell lymphoma","volume":"141","author":"Choi","year":"2019","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106715_bib0245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.1976.tb01873.x","article-title":"Significance of haematological parameters in the non-Hodgkin\u2019s malignant lymphomas","volume":"32","author":"Bloomfield","year":"1976","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2021.106715_bib0250","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/1097-0142(19910301)67:5<1389::AID-CNCR2820670519>3.0.CO;2-Q","article-title":"Clinical significance of hematologic parameters in non-Hodgkin\u2019s lymphoma at diagnosis","volume":"67","author":"Conlan","year":"1991","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:36Z","timestamp":1758934956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621017161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"alternative-id":["S0145212621017161"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106715","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106715"}}